We identified biomarkers of SBA and potential target genes for its treatment, such as CEACAM5 and MUC1. CEACAM5 is a traditional marker used in the clinical diagnosis of many types of cancers including SBA44, and MUC1 is a tumor antigen that is also targeted in many clinical traits of immunotherapies31,45. This evidence concerns the gene CEACAM5 and neoplasm.